Practice-Changing Advances in Systemic Therapies Shaping the Landscape of Lung Cancer in 2025OA
With the rapid advancement of molecular profiling and precision therapeutics,targeted and immunotherapeutic strategies have irrevocably reshaped the pharmacological management for both non-small cell lung cancer(NSCLC)and small cell lung cancer(SCLC).Overall mortality from lung cancer has continued its downward trend over the past decade,and this decline has accelerated,largely driven by advances in early detection and curative-intent surgeries.In parallel,the systemic therapies have undergone a dramatic evolution with the integration of,for example,antibody-drug conjugates(ADCs)and bispecific antibodies(BsAbs).The year 2025 marks a period of significant progress in lung cancer treatment,characterized by groundbreaking therapeutic successes across all disease stages and subtypes.This comprehensive review synthesizes pivotal evidence presented at key oncology forums in 2025 to delineate the substantially evolved clinical landscape.
Zhenyu Zhou;Wanting Gao;Molly S.C.Li;Qing Zhou
Guangdong Lung Cancer Institute,Guangdong Provincial People's Hospital,Guangdong Academy of Medical Sciences,Southern Medical University,Guangzhou,Guangdong,ChinaGuangdong Lung Cancer Institute,Guangdong Provincial People's Hospital,Guangdong Academy of Medical Sciences,Southern Medical University,Guangzhou,Guangdong,China Shantou University Medical College,Shantou,Guangdong,ChinaDepartment of Clinical Oncology,The Chinese University of Hong Kong,Hong Kong,ChinaGuangdong Lung Cancer Institute,Guangdong Provincial People's Hospital,Guangdong Academy of Medical Sciences,Southern Medical University,Guangzhou,Guangdong,China
医药卫生
antibody-drug conjugatesbispecific antibodieslung cancerneoadjuvant immunotherapyltargeted therapyT-cell engagers
《Cancer Innovation》 2026 (3)
P.26-35,10
Guangzhou Science and Technology Program,Grant/Award Number:2025A03J4506National Natural Science Foundation of China,Grant/Award Number:82373349MOE Changjiang Distinguished Professor Supporting Project,Grant/Award Number:KY0120240205Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer,Grant/Award Number:2017B030314120。
评论